Home-grown VIRANORM’ shows breakthrough results in reduction of NL Ratio and increase of cellular immunity in fight against COVID-19.
The Bengaluru based Khoday Group of Industries has rolled out a first of its kind Ayurvedic Immuno-modulator VIRANORM that helped COVID patients recover quickly in a recently coneluded clinical trial. With ViraNorm’, the Khoday Group is making its entry into the field of science-based alternative medicine.
*ViraNorm’ approved by AYUASH has been developed by the Khoday Group in collaboration with Althea DRF Life Sciences: ViraNorm has undergone one of the largest randomized multicentre phase 3 clinical trials in the country for an Ayurvedic formulation. This trial was conducted in leading institutions like Vietoria hospital, Bengaluru, and was carried out in line with international standards for clinical trials.
ViraNorm’ was developed post extensive safety and efficacy studies, and was found to be effective in the clinical trial” says Dr. Manu Jaggi COO, Althea DRF Lifesciences. *ViraNorm helps halt the progression of virus in the body. “ViraNorm’ can therefore be referred to as an add-on therapy/medication for asymptomatic and mildly symptomatic COVID patients. ViraNorm helps in stopping the migration of the patients from mild to moderate condition.
“Neutrophil- Lymphocyte Ratio (NI R) has increasingly come under spotlight as a very useful, rapid and inexpensive prognostic biomarker for COVID-19 patients. where elevated NLR levels may be associated with unfavourable clinical prognosis. In COVID-19 infections, low NLR levels (ratio range between 0.75-3 is considered as normal) may indicate lower inflammation and higher cytotoxic T cell immunity, and may signify lower COVID-19 viral loads, and may aid in better recovery”, says Dr. Radheshyam Naik, a leading Doctor, and the Prineipal Investigator of the ViraNorm clinical trial.
Human body fights against diseases by showing two types of immunities. One, is antibody mediated immunity. and the other is cell mediated immunity”. The newly developed Ayurvedic medicinal product ViraNorm’ was proven to improve the patients’ cell mediated immunity in the clinical trial, thereby helping patients to recover faster.
Further, it was proven in the clinical trial, that, ViraNorm” also reduces both the duration and the severity of cough and breathlessness significantly, which are the primary symptoms of COVID patients. The ingredients in the capsule work by not letting the adhesion of the virus to the cell surface of the individual in nasal or oral cavity regions.
“The reduced NLR ensures reduction in Cellular Level Inflammation and increases Cell Mediated Immunity. This is the only alternative medication which has been systematically proven to reduce NLR in a clinical trial. Since this is developed on fundamental basis of immunity, it may work even for variants of the virus,” says Dr K.G.Padmanaban, who has formulated ViraNorm’.
Human body fights against diseases by showing two types of immunities. One, is *antibody mediated immunity’, and the other is cell mediated immunity. The newly developed Ayurvedic product ViraNorm’ was proven to improve the patients’ cell mediated immunity in the clinical trial, thereby helping patients to recover faster.
Further, it was proven in the clinical trial that ViraNorm’ also reduces both the duration and the severity of cough and breathlessness significantly, which are the primary symptoms of COVID patients.
Swamy Khoday Vice Chairman and Managing Director, Khoday Group of Industries says, “ViraNorm‘, which is found to be very effective in clinical trial, and all the technical details are well cireulated.
“I firmly believe that medicines made out of natural ingredients backed by scientific principles will assist in getting cured from ailments and maintain health with no adverse effects”, Swamy points out.
The Clinical Trial for ViraNorm’ was done in Victoria Hospital and other institutions of Bengaluru, which are NABH (National Accreditation Board for Hospitals) accredited. The trial was done with the approval of CTRI (Clinical Trials Registry- India). For this 250 COVID subjects were randomized and enrolled for the trial that lasted for 6 months. These 250 patients were divided into two arms of 125 cach. One group was administered the ViraNorm’ and other was not. After a detailed analysis of the trial it was found, that those who were administered ViraNorm fared better compared to those who were not administered this medicine.
“Very interestingly, this promotion of T cell immunity and reduction of cellular inflammation seems to be in both younger (less than 40 years), as well as older (more than 60 years) patients. While older patients have always been a vulnerable age group, the ongoing 2nd wave of COVID-19 is also affecting younger patients in large numbers and therefore this observation seems important”, says Rajeev Nagi. a leading healthcare industry expert.
The enhanced Cell Immunity plays its role in long term recovery. ‘ViraNorm’ is also safe for patients suffering from comorbidities such as hypertension and diabetes.
ViraNorm‘ is available at LK Wellness Centre (#75, 3rd Cross, Residency Road, Bengaluru- 560025) and can be contacted on 080-40934216/93801 74977. ViraNorm is priced at Rs 2000/- per bottle of 60 capsules.
City Today News
9341997936
City Today News 